4D Molecular Therapeutics, Inc. (FDMT)
| Market Cap | 721.49M +59.9% |
| Revenue (ttm) | 92.01M +278,712.1% |
| Net Income | -179.18M |
| EPS | -2.77 |
| Shares Out | 55.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 656,370 |
| Open | 13.14 |
| Previous Close | 13.33 |
| Day's Range | 12.87 - 13.44 |
| 52-Week Range | 6.96 - 16.93 |
| Beta | 2.74 |
| Analysts | Strong Buy |
| Price Target | 28.09 (+115.08%) |
| Est. Earnings | Nov 9, 2026 |
About FDMT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is... [Read more]
Financial Performance
In 2025, 4D Molecular Therapeutics's revenue was $85.21 million, an increase of 230194.59% compared to the previous year's $37,000. Losses were -$140.11 million, -12.90% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for FDMT stock is "Strong Buy." The 12-month stock price target is $28.09, which is an increase of 115.08% from the latest price.
News
4DMT to Host Investor Day on October 21, 2026
Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.
4D Molecular price target raised to $33 from $29 at BofA
BofA raised the firm’s price target on 4D Molecular (FDMT) to $33 from $29 and keeps a Buy rating on the shares after the company reported two-year data from the…
Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results
Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 clinical data for its wet age-related macular degenerat...
4D Molecular announces first patients enrolled in 4SIGHT Phase 3 trial
4D Molecular (FDMT) Therapeutics announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular...
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4D Molecular Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The session highlighted the progress of a next-gen gene therapy platform, with 4D-150 advancing in wet AMD and DME. Strong clinical data, rapid trial enrollment, and a robust commercial partnership with Otsuka support global expansion. Two-year data confirm safety and high treatment burden reduction.
4D Molecular upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Josh Schimmer upgraded 4D Molecular (FDMT) to Overweight from Neutral with a $20 price target
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4D Molecular Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Phase III trials for 4D-150 in wet AMD are fully enrolled, with major data readouts expected next year. The therapy aims to significantly reduce injection burden and preserve vision, with strong payer interest and operational readiness for launch.
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
B. Riley views EyePoint study miss as positive for 4D Molecular
B. Riley analyst Mayank Mamtani reiterates a Buy rating on 4D Molecular (FDMT) with a $37 price target after EyePoint (EYPT) reported its Phase 3 clinical trial for Duravyu for…
4D Molecular price target lowered to $32 from $33 at Goldman Sachs
Goldman Sachs analyst Salveen Richter lowered the firm’s price target on 4D Molecular (FDMT) to $32 from $33 and keeps a Buy rating on the shares after its Q2 results.
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 Presented positive 2-year data from 4D-150 PRISM Ph...
4D Molecular Therapeutics Quarterly report: Q2 2026
4D Molecular Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
4D Molecular Therapeutics Earnings release: Q2 2026
4D Molecular Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
4D Molecular initiated with a Buy at B. Riley
B. Riley initiated coverage of 4D Molecular (FDMT) with a Buy rating and $37 price target. 4D-150 is a one-time eye injection that makes the eye produce Eylea continuously and…
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4D Molecular Therapeutics Slides: Corporate presentation
4D Molecular Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 17, 2026.
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4D Molecular completes enrollment in 4FRONT-2 trial
4D Molecular (FDMT) announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program, evaluating 4D-150 in patients with wet age-related macular degeneration. Publ...
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4D Molecular Therapeutics Transcript: AGM 2026
The virtual meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by stockholders. Voting results will be filed with the SEC, and no questions were raised during the Q&A session.
4D Molecular Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing its gene therapy platform with 4D-150 in late-stage trials for wet AMD and DME, targeting significant reductions in treatment burden and aiming for a paradigm shift in retinal care. Key data readouts and trial initiations are expected over the next 12 months.
4D Molecular Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
4D-150, a gene therapy for wet AMD and diabetic eye disease, aims to provide sustained anti-VEGF expression, reducing treatment burden and improving patient outcomes. Phase II data show strong efficacy and safety, with phase III results expected next year. The product is positioned for seamless integration into current practice and significant market impact.